Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Javier, Twelves, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496313/
https://www.ncbi.nlm.nih.gov/pubmed/31782589
http://dx.doi.org/10.1111/tbj.13686
_version_ 1783583068743794688
author Cortes, Javier
Twelves, Chris
author_facet Cortes, Javier
Twelves, Chris
author_sort Cortes, Javier
collection PubMed
description In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0‐6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).
format Online
Article
Text
id pubmed-7496313
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74963132020-09-25 Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis Cortes, Javier Twelves, Chris Breast J Short Communications In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0‐6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01). John Wiley and Sons Inc. 2019-11-29 2020-07 /pmc/articles/PMC7496313/ /pubmed/31782589 http://dx.doi.org/10.1111/tbj.13686 Text en © 2019 The Authors. The Breast Journal published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Cortes, Javier
Twelves, Chris
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title_full Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title_fullStr Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title_full_unstemmed Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title_short Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
title_sort impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496313/
https://www.ncbi.nlm.nih.gov/pubmed/31782589
http://dx.doi.org/10.1111/tbj.13686
work_keys_str_mv AT cortesjavier impactofthenumberofpriorchemotherapyregimensonoutcomesforpatientswithmetastaticbreastcancertreatedwitheribulinaposthocpooledanalysis
AT twelveschris impactofthenumberofpriorchemotherapyregimensonoutcomesforpatientswithmetastaticbreastcancertreatedwitheribulinaposthocpooledanalysis

Ejemplares similares